Diverse vascular lesions in systemic lupus erythematosus and clinical implications

Tan, Ying; Yu, Feng; Liu, Gang

doi:10.1097/01.mnh.0000444812.65002.cb

Cited by 11 publications

(8 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, we found that the probability of SLE patients complicated with serositis was significantly increased if the duration of medicine maintenance therapy less than 1 year. The systemic damage of SLE was induce by vasculitis and non-inflammatory vascular remodeling [38][39][40]. Vasculitis is significantly correlated with the activity of SLE [38], while the pathophysiological mechanisms of noninflammatory vascular remodeling may play an important role when the course of the disease is longer [38,40], which might act as a key factor in the choice of treatment strategy and the prognosis.…”

Section: Discussionmentioning

confidence: 99%

“…The systemic damage of SLE was induce by vasculitis and non-inflammatory vascular remodeling [38][39][40]. Vasculitis is significantly correlated with the activity of SLE [38], while the pathophysiological mechanisms of noninflammatory vascular remodeling may play an important role when the course of the disease is longer [38,40], which might act as a key factor in the choice of treatment strategy and the prognosis. Vascular remodeling erodes multiple organs throughout the body along the course of the disease, and they tend to become chronic, requiring long-term drug control or even lifelong medication.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Risk factors for the flare of systemic lupus erythematosus and its influence on prognosis: a single-center retrospective analysis

et al. 2021

View full text Add to dashboard Cite

Objectives To explore the risk factors for systemic lupus erythematosus (SLE) flare and their impact on prognosis. Methods The clinical characteristics, laboratory results, and treatment plans of 121 patients with SLE flare were retrospectively analyzed. Ninety-eight SLE outpatients with sustained remission during the same period were selected as controls. Logistic multivariate regression analysis was employed to screen for risk factors for SLE flare. Results Infection, thrombocytopenia, arthritis, anti-nucleosome antibodies positive, anti-β2-glycoprotein I (IgG) antibodies positive, and patient’s self-discontinuation of medicine maintenance therapy might be risk factors for SLE flare. Patients who discontinued medicine maintenance therapy by themselves had a significantly higher rate of severe SLE flare than patients with regular medicine maintenance therapy (P = 0.033). The incidence of anemia associated with SLE (P = 0.001), serositis (P = 0.005), and pulmonary hypertension (P = 0.003) in patients who discontinued medicine maintenance therapy were significantly higher than patients with regular medicine maintenance therapy. SLE patients with regular medicine maintenance therapy for less than 3 years had a higher risk of pulmonary hypertension than those with regular medicine maintenance therapy longer than 3 years (P = 0.034). Conclusions The accompanying thrombocytopenia, arthritis, anti-nucleosome antibodies positive and anti-β2-glycoprotein I (IgG) antibodies positive at the onset of SLE may affect the prognosis of SLE. Patient’s self-discontinuation of medicine maintenance therapy is the main cause of SLE flare, which may induce severe flare in SLE patients and lead to a significantly higher incidence of pulmonary hypertension.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Risk factors for the flare of systemic lupus erythematosus and its influence on prognosis: a single-center retrospective analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Treatment with coptisine significantly alleviated the impairment of the vascular relaxation response to the endothelium-dependent vasodilator ACh in SLE mice, which suggests that coptisine may prevent vascular endothelial dysfunction. The mechanisms of endothelial dysfunction in SLE patients may be upregulated expression of ICAM-1 and vascular cell adhesion molecule-1 (VCAM-1), increased secretion of chemokines such as MCP-1, IL-6, IL-17A, and TNF-a, and the promotion of the activation of the transcription factor NF-kB p65 in human endothelial cells by immune complexes (Goḿez-Guzmań et al, 2014;Tan et al, 2014). In this study, we found that coptisine significantly alleviated the overexpression of ICAM-1 and IL-17A in the serum.…”

Section: A B Cmentioning

confidence: 99%

Coptisine Alleviates Pristane-Induced Lupus-Like Disease and Associated Kidney and Cardiovascular Complications in Mice

Zhang

Chen

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Systemic lupus erythaematosus (SLE) is a chronic multi-system autoimmune disease with a high prevalence of kidney and cardiovascular complications. Considering that Rho-associated coiled-coil-containing protein kinases (ROCKs) play important roles in SLE, inflammation, and cardiovascular disease, we hypothesized that coptisine, which has been found to inhibit ROCKs, may have an effect on SLE. The effect of coptisine was assessed in female BALB/c mice intraperitoneally injected with 0.5 mL of pristane. Serum autoantibodies were tested every month, blood pressure was measured every 2 months, and serum inflammatory markers, spleen pathologic characteristics, renal injury and vascular function were observed at 6 months. The results showed that coptisine decreased the levels of serum autoantibodies and serum inflammatory markers in the SLE mice, improved the pathologic characteristics of the spleen, and simultaneously improved renal injury, decreased inflammatory responses in the kidneys, reduced blood pressure, and improved vascular endothelial function. Western blot assays revealed that inhibiting the activation of the NF-kB and Rho/ ROCK signalling pathways and downstream signalling molecules might be the potential mechanisms of the effects of coptisine. Our findings suggest that therapy with coptisine may be a strategy for preventing SLE and ameliorating associated kidney and cardiovascular complications.

show abstract

“…Therefore, it is still controversial whether renal vascular complications should be considered independent renal prognostic factors for SLE. A series of studies indicated that renal vascular complications are closely associated with clinical disease, disease activity, and renal outcomes, and that renal thrombotic microangiopathy (TMA) is an independent risk factor for the renal prognosis of patients with long-term LN [34,[38][39][40][41].…”

Section: Vascular Lesionsmentioning

confidence: 99%

Renal involvement in systemic lupus erythematosus: additional histopathological lesions

et al. 2020

View full text Add to dashboard Cite

A common criticism of the classification of lupus nephritis is the relative scarcity of information regarding tubular, interstitial, and vascular changes compared to the available information regarding glomerular changes, even though their potential for independent progression is known. This study reviewed the importance of less explored lesions by the current and widely used 2003 classification of lupus nephritis of the International Society of Nephrology/Renal Pathology Society (ISN/RPS), with emphasis on the tubulointerstitial, podocyte, and vascular lesions, increasingly recognised as being important in the pathogenesis and prognosis of the disease. Recognition of these lesions can help with therapeutic decision-making, thereby allowing better results for patients with systemic lupus erythematosus.

show abstract

Diverse vascular lesions in systemic lupus erythematosus and clinical implications

Cited by 11 publications

References 39 publications

Risk factors for the flare of systemic lupus erythematosus and its influence on prognosis: a single-center retrospective analysis

Risk factors for the flare of systemic lupus erythematosus and its influence on prognosis: a single-center retrospective analysis

Coptisine Alleviates Pristane-Induced Lupus-Like Disease and Associated Kidney and Cardiovascular Complications in Mice

Renal involvement in systemic lupus erythematosus: additional histopathological lesions

Contact Info

Product

Resources

About